Cetraxal is a newly approved eardrop formulation of ciprofloxacin. It is a sterile 0.2% solution that contains no preservatives.
Ciprofloxacin is an antibiotic in the fluoroquinolone family, which are associated with rare but severe side effects. Systemic forms (oral and intravenous administration) carry a "black box warning" for tendinitis leading to permanent joint damage. Cetraxal has an advantage over these forms because the eardrop form does not spread systemically, making it far less dangerous.
In clinical studies, 70% of patients were cured of their condition after treatment with Cetraxal—but the same was true for 60% of patients treated by placebo. Therefore, it is probably most useful for patients with stubborn infections that show no signs of clearing up without it. Doctors may decide to prescribe the drug even for new infections, if they fear that non-treatment could lead to complications. If you have concerns after being prescribed, talk to your health care provider about risks, benefits, and other options.